Aditxt, Inc. Completes Preclinical Studies for Adimune Immune Modulation Therapeutic Platform

Aditxt, Inc. (NASDAQ:ADTX) recently disclosed in a Form 8-K submission to the Securities and Exchange Commission that its subsidiary, Adimune, Inc., has successfully concluded preclinical efficacy and safety studies for its immune modulation therapeutic platform.

The company released a press statement on December 12, 2024, unveiling the positive outcomes of Adimune’s preclinical studies. The detailed findings of these studies are now public as part of the Form 8-K filing, enclosed as Exhibit 99.1.

Furthermore, Aditxt, Inc. reported that it has crafted presentation materials specifically related to Adimune. These materials were made available on Adimune’s official website on December 11, 2024, and have also been presented in the Form 8-K submission as Exhibit 99.2.

It is essential to note that the information furnished in this regulatory disclosure, including Exhibit 99.1 and Exhibit 99.2, is considered disclosed for informational purposes and shall not be deemed as a filed document under the Securities Exchange Act of 1934. As per the disclosure, this provided data will not be incorporated by reference in any filings under the Securities Act of 1933 or the Exchange Act in the future.

As an emerging growth company, Aditxt, Inc. continues to make strides in biotechnology and aims to further develop its innovative immune modulation therapeutic platform. Investors and stakeholders in the healthcare and biotech sectors will be closely monitoring the progress and future developments of Aditxt’s subsidiary, Adimune.

The company’s stock, trading under the symbol ADTX on The Nasdaq Stock Market LLC, may respond to this recent positive update as the market digests the implications of the successful preclinical studies conducted by Adimune.

This data provides valuable insight into the advancements and potential of Aditxt, Inc. and its subsidiary within the biopharmaceutical landscape, signaling significant strides in their research and development endeavors.

Contact:
Aditxt, Inc.
2569 Wyandotte Street, Suite 101, Mountain View, CA 94043
Phone: (650) 870-1200

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aditxt’s 8K filing here.

About Aditxt

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.